Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
I am upgrading Thermo Fisher Scientific Inc. to a “Buy” with a fair value of $610 per share due to anticipated recovery in the pharma and biotech industries. Thermo Fisher's high-impact innovations and strategic M&A, including the acquisition of Olink, support a 7%-9% organic revenue growth and mid-teens EPS growth. Q3 results show stabilization in life sciences, with raised full-year adjusted EPS guidance, maintaining revenue guidance of $42.4 to $43.3 billion.
Thermo Fisher Scientific (TMO) Q3 Earnings Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $5.25 per share. This compares to earnings of $5.69 per share a year ago.
Thermo Fisher raises profit forecast on strong demand for its tools and services
Thermo Fisher Scientific on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved demand for its tools and services used in drug development.
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Thermo Fisher has outperformed the market with a 420%+ return over the past decade, but its current valuation is high. The company's recent results show mixed performance, with slight revenue decline, but improved earnings-per-share and raised 2024 guidance. Despite strong growth prospects and market tailwinds, the stock's high valuation and low dividend yield make it a hold for now.
Exclusive: Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
